**
Recent findings have revealed a concerning association between the weight-loss medication Wegovy and a heightened risk of sudden vision loss, particularly when compared to its diabetes counterpart, Ozempic. A comprehensive study published in the British Journal of Ophthalmology highlights that individuals using Wegovy are nearly five times more likely to experience non-arteritic anterior ischemic optic neuropathy (Naion), a condition often described as an “eye stroke,” causing irreversible vision impairment.
Study Overview and Key Findings
The research scrutinised data from the US Food and Drug Administration’s adverse event reporting system, spanning from December 2017 to December 2024. It specifically focused on reports of Naion among users of semaglutide-based medications, including Wegovy, Ozempic, and Rybelsus, as well as tirzepatide (Mounjaro). Notably, patients taking Wegovy, which is marketed for weight management, exhibited a significantly elevated risk of Naion in contrast to those on Ozempic, which is prescribed for type 2 diabetes.
Dr. Edward Margolin, an ophthalmology specialist from the University of Toronto and a co-author of the study, indicated that the rapid weight loss associated with Wegovy could be a contributing factor to this increased risk. The study highlighted that men were particularly susceptible, facing a risk three times greater than that of women.
Mechanisms Behind Vision Loss
Naion occurs when there is a sudden reduction in blood flow to the optic nerve, leading to potentially permanent vision loss. While the incidence of this condition is low—approximately one in 10,000 individuals taking semaglutide—the study posits a “potential dose-dependent safety concern.” The faster absorption and higher dosages of Wegovy compared to Ozempic may account for the stronger association with sudden sight loss.
The research team’s analysis found no significant risk of Naion linked to Rybelsus or tirzepatide, suggesting that the formulation and administration methods of these drugs might influence the likelihood of adverse effects.
Regulatory Responses and Expert Opinions
In light of these findings, the UK Medicines and Healthcare products Regulatory Agency (MHRA) issued a drug safety update earlier this year, cautioning about the risk of Naion associated with semaglutide. Dr. Alison Cave, MHRA’s chief safety officer, reassured patients that while the risk remains extremely low, it is crucial for both patients and healthcare providers to be vigilant regarding potential symptoms of this condition.
Samantha Mann, a consultant ophthalmologist and diabetic eye screening lead at the Royal College of Ophthalmologists, emphasised the limitations of the study, noting that it relied on reported side effects and could not definitively establish causation. She mentioned that instances of optic nerve strokes have not been frequently observed in routine clinical settings, underscoring the need for further research to ascertain the validity of the findings.
Novo Nordisk, the manufacturer of these medications, stated that patient safety is paramount and that they are committed to closely monitoring the safety profiles of their products. They have updated EU patient leaflets for Wegovy, Ozempic, and Rybelsus to reflect the association with Naion, while maintaining that the overall risk-benefit profile of semaglutide remains favourable.
Why it Matters
The implications of this research extend beyond individual health risks; they highlight a significant concern in the realm of public health regarding the safety of weight-loss medications. As more patients turn to pharmacological solutions for obesity and diabetes management, understanding the potential side effects becomes critical. This study not only raises awareness about the risks associated with semaglutide but also calls for enhanced scrutiny and further investigation into the long-term effects of such medications, ensuring that patient safety remains at the forefront of pharmaceutical development and regulation.
